PT-141 (Bremelanotide): Melanocortin Receptor Research
PT-141 is a synthetic analog of alpha-MSH that acts on melanocortin receptors in the central nervous system. This article reviews the research pathway from MT-II to its approved derivative and the science of melanocortin signaling.
Background: The Melanocortin System
Melanocortins are peptides derived from the precursor protein proopiomelanocortin (POMC). They act on a family of G-protein coupled receptors (MC1R–MC5R) that regulate diverse physiological functions including pigmentation, inflammation, energy homeostasis, and sexual function.
From Melanotan II to PT-141
Melanotan II (MT-II) is a cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH). Research into MT-II revealed significant effects on sexual arousal in addition to its intended tanning effects. PT-141 (Bremelanotide) was subsequently developed as a more selective compound targeting MC3R and MC4R, eliminating the tanning effect while retaining the central effects on arousal.
Bremelanotide received FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism of Action
Unlike PDE5 inhibitors (e.g., sildenafil) that act peripherally on vascular smooth muscle, PT-141 acts centrally:
- Binds MC3R and MC4R in the hypothalamus and limbic system
- Activates neural pathways involved in sexual motivation
- Does not require sexual stimulation as a prerequisite
Preclinical Research
Animal studies explored:
- Spontaneous erection models in rats
- Female sexual motivation assays
- Central neural circuit mapping using c-Fos immunohistochemistry
Research on MC4R
MC4R is also implicated in energy balance and obesity research. PT-141's activity at this receptor has prompted research into metabolic applications independent of its sexual health pathway.
Side Effects Observed in Research
Nausea and transient increases in blood pressure have been observed in clinical research. The approved formulation uses subcutaneous injection with specific dosing guidance.
Conclusion
PT-141's trajectory from sunscreen research to FDA approval illustrates how unexpected findings in peptide research can lead to novel therapeutic applications. Its central mechanism of action distinguishes it from all prior compounds in its class.
Research Disclaimer
This article is intended for educational and research purposes only. All products referenced are for laboratory research use only and are not approved for human or animal consumption. PeptidXs does not provide medical advice.
